Member Info for moorlaner

Looking back at the details PHE raised £10m at 5.5p per share. I was annoyed at the time but now I'm very happy not to be sitting on a further 35% loss !!! Perhaps there is a structural weakness in our agreement with Peel in that they do not have to put their hands in their pockets until they are ready. So we are not masters of our own UK destiny. If i am wrong then please let me know. For the future I will now be keeping a close eye on EQTEC who seem to be focussed on getting projects up and running.

"we will hear on the 13th just what CK thinks about this, i have said many times that he will be absolutely lynched, but its not his fault its the government ******* about and this is one of the downsides of having a government for a customer."

You have identified the biggest risk for ODX. Anyone who has had dealings with Public bodies knows that they are frightened of their own shadow, and this leads to contracts of much complexity. The only upside is usually in the quantity and the certainty of payment. (well it used to be until recently) .

If the Innova test is only right half the time then a lot of money could be saved by just advising the population to toss a coin if they have symptoms!!

ffg in the bin !! The reason for the share price being less that we expect is because ODX are awaiting the HMG to put in actual orders and not just promises. Anyone who has dealt with Civil servants on contract matters and Orders would know how tricky it can be and this I guess is why there is a reticence of new investors to drive the price up.

I dont know if GLAXO count as one of the big boys anymore as their share price has been in the doldrums for so long. But might they try an approach to get them back on track??

https://twitter.com/i/status/1282641383715733504

so if anyone was waiting in the wings to take over BT have they left it too late???

The penny will drop eventually with realisation that the virus has changed the world forever, and as a consequence testing will be here for a long time to come.

Vaccines cannot be rolled out quickly enough in volume to make any significant difference to the world’s population for years to come. If like some other vaccines immunity doesn't last, and like the flu jab there are annual variants, then this virus is going to be a problem for many, many years, Unlike the flu there is no inbuilt resistance in the general population. So at the moment it is highly infectious and has a payload which is to be avoided, ie death in our everly increasing elderly population, or severely debilitating consequences in younger age groups for some.

The only way out and a return to what we used to call normal is as the WHO originally said TEST TEST TEST. This will suppress the transmission but never totally control the situation.

So I think we should be a lot more relaxed about Avacta’s timescale to roll out the antigen kits. Patience and a best in class test will bring reward. I will be very surprised if we are not looking at multiples of the current share price this time next year. So as part of a diverse portfolio it is a reasonable punt??

These tweets all indicate everything is in progress and perhaps we should chill a little bit???

Nov 10
We continue to make very good progress with a rapid antigen test and with the laboratory based mass spectrometry test. We are preparing for the first clinical evaluation of the rapid antigen test and will update the market fully when that study begins. #AVCT 4/6
Avacta
@avacta
·
Nov 10
We are conducting a clinical evaluation of the BAMS assay at several sites in the UK and will update the market shortly when we have those data. We continue to make significant commercial progress for these tests, and the SARS-CoV-2 spike protein research ELISA. #AVCT 5/6
Avacta
@avacta
·
Nov 10
We are also on track to make the regulatory submission for the first of Avacta’s revolutionary tumour activated chemotherapies, AVA600 pro-doxorubicin, in 2020 and dose first patients in the UK in early 2021. #AVCT

listen to the content, not the delivery. pathethic

blue tiger i am not a statto. You may be, I know not. But as a layman what the term "statistically non-significant" means to me is that the sample size was not sufficiently large to prove beyond doubt their findings. ie randomness chance or whatever you like to call it could give an excellent result. It is only by having a sufficiently large sample you can make statements of significance. Combining c and d cohorts increased the sample size and made the results for a c and d sample statistically significant. Would any Statto care to comment please. Thank you

I'll take £4 . !!!!

Is he needed here???

I too lost a fair chunk on SXX. In looking for further opportunities for my reduced wedge I have found HZM. This is not a ramping post but just an informative one for those still with an appetite for holes in the ground! This interview is reasonably instructive. https://www.brrmedia.co.uk/broadcasts/5f33cbb3b14d872626436c62/horizonte-minerals-us325m-senior-debt-facility-mandate-for-araguaia GLA

"OGA have said last years 9800bbopd find can't be tied back to AM, that is probably there final answer, even though HURR/Spirit may continue to argue the case. So they will have to PA the well but the oil is there & the probably will come back to it at a later date."

Can anyone explain to me in layman's language why the OGA have adopted this stance? Thx

shouldn't we be a bit more up today as a result of the 15% holding in Oxford Nanopore.? It is the only reason I am still holding this woofer.

A sensible move as well as recognising the adverse business/tax environment in India